ArticleClinical Medicine Insights. Oncology2011
Bevacizumab for the treatment of recurrent glioblastoma.
Article in Clinical Medicine Insights. Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 132 citations in OpenAlex.
- A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.Journal of translational medicine · 2017Trial
- AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.Neuro-oncology · 2016Trial
- Trial
- Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.The AAPS journal · 2014Trial
- Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.BioMed research international · 2014Trial
- Management of persistent residual growth of high-grade glioma: a case report highlighting clinical and therapeutic challenges.Oxford medical case reports · 2025Article
- Antibody-conjugated polymer nanoparticles for brain cancer.Drug delivery and translational research · 2025Review
- Carmustine Wafers (Gliadel) in Brain Metastases: Revisiting an Old Concept With New Insights.Cureus · 2025Article
- Detecting glioblastoma infiltration beyond conventional imaging tumour margins using MTE-NODDI.Imaging neuroscience (Cambridge, Mass.) · 2025Article
- Fibronectin Type III Domain Containing 3B as a Potential Prognostic and Therapeutic Biomarker for Glioblastoma.Biomedicines · 2023Article
- Dexamethasone and compliance affect TTFields efficacy to glioblastoma patients: a systematic review and meta-analysis.Chinese neurosurgical journal · 2022Review
- Promising Chemotherapy for Malignant Pediatric Brain Tumor in Recent Biological Insights.Molecules (Basel, Switzerland) · 2022Review
- Involvement of N-methylpurine DNA glycosylase in resistance to temozolomide in patient-derived glioma cells.Scientific reports · 2020Article
- Novel Molecular Markers in Glioblastoma-Benefits of Liquid Biopsy.International journal of molecular sciences · 2020Review
- Coding of Glioblastoma Progression and Therapy Resistance through Long Noncoding RNAs.Cancers · 2020Review
- Arming Anti-EGFRvIII CAR-T With TGFβ Trap Improves Antitumor Efficacy in Glioma Mouse Models.Frontiers in oncology · 2020Article
- Extracellular matrix differences in glioblastoma patients with different prognoses.Oncology letters · 2019Article
- Turning "Cold" Into "Hot" Tumors-Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers.Frontiers in oncology · 2019Review
- Tumour treating fields in a combinational therapeutic approach.Oncotarget · 2018Review
- Survival prediction based on qualitative MRI diffusion signature in patients with recurrent high grade glioma treated with bevacizumab.Quantitative imaging in medicine and surgery · 2018Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in upfront therapy, the prognosis in the great majority of patients with glioblastoma (GBM) is poor as almost all recur and result in disease-related death. Glioblastoma are highly vascularized cancers with elevated expression levels of vascular endothelial growth factor (VEGF), the dominant mediator of angiogenesis. A compelling biologic rationale, a need for improved therapy, and positive results from studies of bevacizumab in other cancers led to the evaluation of bevacizumab in the treatment of recurrent GBM. Bevacizumab, a humanized monoclonal antibody that targets VEGF, has been shown to improve patient outcomes in combination with chemotherapy (most commonly irinotecan) in recurrent GBM, and on the basis of positive results in two prospective phase 2 studies, bevacizumab was granted accelerated approval by the US Food and Drug Administration (FDA) as a single agent in recurrent GBM. Bevacizumab therapy is associated with manageable, class-specific toxicity as severe treatment-related adverse events are observed in only a minority of patients. With the goal of addressing questions and controversies regarding the optimal use of bevacizumab, the objective of this review is to provide a summary of the clinical efficacy and safety data of bevacizumab in patients with recurrent GBM, the practical issues surrounding the administration of bevacizumab, and ongoing investigations of bevacizumab in managing GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.